By Erin Marie Daly ( January 29, 2008, 12:00 AM EST) -- Merck & Co. and Schering-Plough Corp. face a rising tide of controversy over Vytorin, as the attorneys general of two states investigate whether the companies suppressed the results of a study that found that the drug worked no better than an older, cheaper drug to prevent the buildup of arterial plaque....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.